Neurobiologie der Zwangsstörung

Zusammenfassung

In dieser Übersicht werden pathophysiologische Konzepte der Zwangsstörung vor dem Hintergrund aktueller neurobiologischer Befunde vorgestellt. Diese speisen sich aus klinischer und experimenteller Pharmakologie, Neurobildgebung sowie Neurophysiologie und entwickeln sich in Wechselwirkung mit neurologischen Konzepten von Basalganglienerkrankungen, speziell dem Tourette-Syndrom. Neue Analysen von Genpolymorphismen und Symptomausprägung unterstützen nicht nur die Heredität, sondern auch die genetische Heterogenität der Störung, die sich wahrscheinlich mittelbar in differenzierteren diagnostischen, aber auch therapeutischen Konzepten niederschlagen wird.

Summary

In this review we discuss pathophysiological concepts of obsessive-compulsive disorder (OCD) based on current neurobiological findings. Neurobiological concepts of OCD are based on findings from clinical and experimental pharmacology, neuroimaging and neurophysiology. They have been developed with reference to neurological disorders of the basal ganglion, in particular the Tourette syndrome. Current associations of genetic polymorphisms with clinical phenotypes support both, heredity and genetic heterogeneity of the disorder. Indirectly, these observations will have an impact on diagnostic concepts and even treatment of OCD.

Schlüsselwörter

Zwang - Basalganglion - orbitofrontaler Kortex - Tourette-Syndrom

Keywords

OCD - basal ganglion - orbitofrontal cortex - Tourette syndrome

• Literatur

• 1 Alexander GE, Crutcher MD, DeLong MR. Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, “prefrontal” and limbic functions. Prog Brain Res 1990; 85: 119-46.
• 2 Arnold PD, Sicard T, Burroughs E, Richter MA, Kennedy JL. Glutamate transporter gene SLC1A1 associated with obsessive-compulsive disorder. Arch Gen Psychiatry 2006; 63: 769-76.
• 3 Baxter LR. et al. Brain Mediation of Obsessive-Compulsive Disorder Symptoms: Evidence From Functional Brain Imaging Studies in the Human and Nonhuman Primate. Semin Clin Neuropsychiatry 1996; 01: 32-47.
• 4 Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry 2006; 11: 622-32.
• 5 Canales JJ, Graybiel AM. A measure of striatal function predicts motor stereotypy. Nat Neurosci 2000; 03: 377-83.
• 6 Chamberlain SR. et al. Orbitofrontal dysfunction in patients with obsessive-compulsive disorder and their unaffected relatives. Science 2008; 321: 421-2.
• 7 Clarke HF, Robbins TW, Roberts AC. Lesions of the medial striatum in monkeys produce perseverative impairments during reversal learning similar to those produced by lesions of the orbitofrontal cortex. J Neurosci 2008; 28: 10972-82.
• 8 den Braber A. et al. An fMRI study in monozygotic twins discordant for obsessive-compulsive symptoms. Biol Psychol 2008; 79: 91-102.
• 9 el Mansari M, Bouchard C, Blier P. Alteration of serotonin release in the guinea pig orbito-frontal cortex by selective serotonin reuptake inhibitors. Relevance to treatment of obsessive-compulsive disorder. Neuropsychopharmacology 1995; 13: 117-27.
• 10 Feygin DL, Swain JE, Leckman JF. The normalcy of neurosis: evolutionary origins of obsessive-compulsive disorder and related behaviors. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 854-64.
• 11 Fullana MA. et al. Personality characteristics in obsessive-compulsive disorder and individuals with subclinical obsessive-compulsive problems. Br J Clin Psychol 2004; 43: 387-98.
• 12 Hanna GL, Himle JA, Curtis GC, Gillespie BW. A family study of obsessive-compulsive disorder with pediatric probands. Am J Med Genet B Neuropsychiatr Genet 2005; 134: 13-9.
• 13 Hettema JM, Neale MC, Kendler KS. A review and meta-analysis of the genetic epidemiology of anxiety disorders. Am J Psychiatry 2001; 158: 1568-78.
• 14 Kluge M, Schussler P, Kunzel HE, Dresler M, Yassouridis A, Steiger A. Increased nocturnal secretion of ACTH and cortisol in obsessive compulsive disorder. J Psychiatr Res 2007; 41: 928-33.
• 15 Kordon A. et al. Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study. J Clin Psychopharmacol 2008; 28: 550-4.
• 16 Kordon A, Zurowski B, Hohagen F. Zwangsstörungen. In: Holsboer F, Gründer G, Benkert O. (Hrsg). Handbuch der Psychopharmakotherapie. Berlin: Springer; 2008
• 17 Kulkarni J. et al. Estrogen in severe mental illness: a potential new treatment approach. Arch Gen Psychiatry 2008; 65: 955-60.
• 18 Leckman JF, Mayes LC, Feldman R, Evans DW, King RA, Cohen DJ. Early parental preoccupations and behaviors and their possible relationship to the symptoms of obsessive-compulsive disorder. Acta Psychiatr Scand Suppl 1999; 396: 1-26.
• 19 Liang KY. et al. Evidence for potential relationship between SLC1A1 and a putative genetic linkage region on chromosome 14q to obsessive-compulsive disorder with compulsive hoarding. Am J Med Genet B Neuropsychiatr Genet 2008; 147B: 1000-2.
• 20 Maia AS, Barbosa ER, Menezes PR, Miguel ECFilho. Relationship between obsessive-compulsive disorders and diseases affecting primarily the basal ganglia. Rev Hosp Clin Fac Med Sao Paulo 1999; 54: 213-21.
• 21 Maina G, Albert U, Bogetto F, Vaschetto P, Ravizza L. Recent life events and obsessive-compulsive disorder (OCD): the role of pregnancy/delivery. Psychiatry Res 1999; 89: 49-58.
• 22 Mataix-Cols D, Rosario-Campos MC, Leckman JF. A multidimensional model of obsessive-compulsive disorder. Am J Psychiatry 2005; 162: 228-38.
• 23 Menzies L. et al. Neurocognitive endophenotypes of obsessive-compulsive disorder. Brain 2007; 130: 3223-36.
• 24 Miguel EC. et al. Obsessive-compulsive disorder phenotypes: implications for genetic studies. Mol Psychiatry 2005; 10: 258-75.
• 25 Moresco RM. et al. Fluvoxamine treatment and D2 receptors: a pet study on OCD drug-naive patients. Neuropsychopharmacology 2007; 32: 197-205.
• 26 Nestadt G. et al. A family study of obsessive-compulsive disorder. Arch Gen Psychiatry 2000; 57: 358-63.
• 27 Nordstrom EJ, Burton FH. A transgenic model of comorbid Tourette’s syndrome and obsessive-compulsive disorder circuitry. Mol Psychiatry 2002; 07: 617-25.
• 28 Ogai M, Iyo M, Mori N, Takei N. A right orbitofrontal region and OCD symptoms: a case report. Acta Psychiatr Scand 2005; 111: 74-6.
• 29 Pauls DL, Alsobrook 2nd JP, Goodman W, Rasmussen S, Leckman JF. A family study of obsessivecompulsive disorder. Am J Psychiatry 1995; 152: 76-84.
• 30 Pittenger C, Krystal JH, Coric V. Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx 2006; 03: 69-81.
• 31 Rosenberg DR, MacMillan S. Imaging and neurocircuitry of OCD. In: Davis KL, Charney D, Coyle JT, Nemeroff C. editors. Neuropsychopharmacology: The fifth generation of progress: American College of Neuropsychopharmacology. 2002: 1621-45.
• 32 Schwartz J. Brain lock: Free yourself from obsessivecompulsive disorder. New York: Regan Books/ Harper Collins; 1996
• 33 Shugart YY, Wang Y, Samuels JF, Grados MA, Greenberg BD, Knowles JA. et al. A family-based association study of the glutamate transporter gene SLC1A1 in obsessive-compulsive disorder in 378 families. Am J Med Genet B Neuropsychiatr Genet. 2009 im Druck
• 34 Stewart SE. et al. Association of the SLC1A1 glutamate transporter gene and obsessive-compulsive disorder. Am J Med Genet B Neuropsychiatr Genet 2007; 144B: 1027-33.
• 35 Thobois S, Jouanneau E, Bouvard M, Sindou M. Obsessive-compulsive disorder after unilateral caudate nucleus bleeding. Acta Neurochir (Wien) 2004; 146: 1027-31.
• 36 Tolin DF, Frost RO, Steketee G. An open trial of cognitive-behavioral therapy for compulsive hoarding. Behav Res Ther 2007; 45: 1461-70.
• 37 Veenstra-VanderWeele J, Kim SJ, Gonen D, Hanna GL, Leventhal BL, Cook Jr EH. Genomic organization of the SLC1A1/EAAC1 gene and mutation screening in early-onset obsessive-compulsive disorder. Mol Psychiatry 2001; 06: 160-7.
• 38 Wendland JK. et al. A haplotype containing quantitative trait loci for SLC1A1 gene expression and its association with obsessive-compulsive disorder. Arch Gen Psychiatry 2009; 66: 408-16.
• 39 Westenberg HG, Fineberg NA, Denys D. Neurobiology of obsessive-compulsive disorder: serotonin and beyond. CNS Spectr 2007; 12: 14-27.
• 40 Williams KE, Koran LM. Obsessive-compulsive disorder in pregnancy, the puerperium, and the premenstruum. J Clin Psychiatry 1997; 58: 330-4.
• 41 Zurowski B, Wahl K, Hohagen F, Kordon A. Symptom remission in OCD after discontinuation of pharmacotherapy with fluoxetine: a case for looking beyond serotonin. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 959-60.
• 42 Zurowski B, Kordon A, Wahl K, Hohagen F. Non-selective effects of selective serotonin reuptake inhibitors. Biol Psychiatry 2008; 63: e5.
• 43 Zurowski B, Hohagen F, Kordon A. Neurobiologie der Zwangsstörung. Teil 2: Konzepte und Befunde aus der Neurobildgebung. Nervenheilkunde. 2009 28. in Druck